Patents Assigned to SANIFIT THERAPEUTICS S.A.
-
Publication number: 20230248749Abstract: The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease.Type: ApplicationFiled: April 11, 2023Publication date: August 10, 2023Applicant: SANIFIT THERAPEUTICS, S.A.Inventors: Mohamad Firas BASSISSI, Carolina SALCEDO ROCA, Joan PERELLÓ BESTARD, Miquel David FERRER REYNÉS, María Del Mar PÉREZ FERRER
-
Publication number: 20220339171Abstract: The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.Type: ApplicationFiled: March 17, 2022Publication date: October 27, 2022Applicant: SANIFIT THERAPEUTICS, S.A.Inventors: Joan PERELLÓ BESTARD, Carolina SALCEDO ROCA, Miquel David FERRER REYNÉS
-
Publication number: 20220249521Abstract: Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.Type: ApplicationFiled: April 25, 2022Publication date: August 11, 2022Applicant: Sanifit Therapeutics S.A.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Miguel David FERRER REYNES, Bernat ISERN AMENGUAL, Pieter H. JOUBERT
-
Publication number: 20220000889Abstract: The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease.Type: ApplicationFiled: July 20, 2021Publication date: January 6, 2022Applicant: SANIFIT THERAPEUTICS, S.A.Inventors: Mohamad Firas BASSISSI, Carolina SALCEDO ROCA, Joan PERELLÓ BESTARD, Miquel David FERRER REYNÉS, María Del Mar PÉREZ FERRER
-
Patent number: 11162958Abstract: The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.Type: GrantFiled: February 17, 2017Date of Patent: November 2, 2021Assignee: Sanifit Therapeutics S.A.Inventors: Joan Perello Bestard, Ciriaco Maraschiello De Zuani, Irene Lentheric, Paula Mendoza De Las Heras, Fernando Tur Espinosa, Eva Tur Tur, Maximo Encabo Alarcon, Eva Martin Becerra, Maria de Mar Benito Amengual, Bernat Isern Amengual
-
Publication number: 20210290642Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.Type: ApplicationFiled: March 4, 2021Publication date: September 23, 2021Applicant: SANIFIT THERAPEUTICS S.A.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Ana-Zeralda CANALS HAMANN
-
Patent number: 10973838Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.Type: GrantFiled: February 14, 2020Date of Patent: April 13, 2021Assignee: SANIFIT THERAPEUTICS S.A.Inventors: Joan Perello Bestard, Carolina Salcedo Roca, Ana-Zeralda Canals Hamann
-
Publication number: 20200179422Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Applicant: SANIFIT THERAPEUTICS S.A.Inventors: Joan PERELLO BESTARD, Carolina SALCEDO ROCA, Ana-Zeralda CANALS HAMANN